These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 27043281)

  • 61. ABCG2 is upregulated in Alzheimer's brain with cerebral amyloid angiopathy and may act as a gatekeeper at the blood-brain barrier for Abeta(1-40) peptides.
    Xiong H; Callaghan D; Jones A; Bai J; Rasquinha I; Smith C; Pei K; Walker D; Lue LF; Stanimirovic D; Zhang W
    J Neurosci; 2009 Apr; 29(17):5463-75. PubMed ID: 19403814
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Efavirenz does not interact with the ABCB1 transporter at the blood-brain barrier.
    Dirson G; Fernandez C; Hindlet P; Roux F; German-Fattal M; Gimenez F; Farinotti R
    Pharm Res; 2006 Jul; 23(7):1525-32. PubMed ID: 16779703
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Astrocyte-mediated regulation of multidrug resistance p-glycoprotein in fetal and neonatal brain endothelial cells: age-dependent effects.
    Baello S; Iqbal M; Gibb W; Matthews SG
    Physiol Rep; 2016 Aug; 4(16):. PubMed ID: 27796269
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Overcoming the blood-brain barrier to taxane delivery for neurodegenerative diseases and brain tumors.
    Rice A; Michaelis ML; Georg G; Liu Y; Turunen B; Audus KL
    J Mol Neurosci; 2003; 20(3):339-43. PubMed ID: 14501017
    [TBL] [Abstract][Full Text] [Related]  

  • 65. The role of the efflux transporter, P-glycoprotein, at the blood-brain barrier in drug discovery.
    Cox B; Nicolaï J; Williamson B
    Biopharm Drug Dispos; 2023 Feb; 44(1):113-126. PubMed ID: 36198662
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Participation of Monocarboxylate Transporter 8, But Not P-Glycoprotein, in Carrier-Mediated Cerebral Elimination of Phenytoin across the Blood-Brain Barrier.
    Jomura R; Akanuma SI; Bauer B; Yoshida Y; Kubo Y; Hosoya KI
    Pharm Res; 2021 Jan; 38(1):113-125. PubMed ID: 33527223
    [TBL] [Abstract][Full Text] [Related]  

  • 67. A co-culture-based model of human blood-brain barrier: application to active transport of indinavir and in vivo-in vitro correlation.
    Megard I; Garrigues A; Orlowski S; Jorajuria S; Clayette P; Ezan E; Mabondzo A
    Brain Res; 2002 Feb; 927(2):153-67. PubMed ID: 11821009
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Blood-Brain Barrier in a Haemophilus influenzae Type a In Vitro Infection: Role of Adenosine Receptors A
    Caporarello N; Olivieri M; Cristaldi M; Scalia M; Toscano MA; Genovese C; Addamo A; Salmeri M; Lupo G; Anfuso CD
    Mol Neurobiol; 2018 Jun; 55(6):5321-5336. PubMed ID: 28921456
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Borneol Depresses P-Glycoprotein Function by a NF-κB Signaling Mediated Mechanism in a Blood Brain Barrier in Vitro Model.
    Fan X; Chai L; Zhang H; Wang Y; Zhang B; Gao X
    Int J Mol Sci; 2015 Nov; 16(11):27576-88. PubMed ID: 26593909
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Increasing Intracellular Levels of Iron with Ferric Ammonium Citrate Leads to Reduced P-glycoprotein Expression in Human Immortalised Brain Microvascular Endothelial Cells.
    Newman SA; Pan Y; Short JL; Nicolazzo JA
    Pharm Res; 2021 Jan; 38(1):97-111. PubMed ID: 33532991
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Recent advances in the in vitro and in vivo methods to assess impact of P-glycoprotein and breast cancer resistance protein transporters in central nervous system drug disposition.
    Chatterjee S; Deshpande AA; Shen H
    Biopharm Drug Dispos; 2023 Feb; 44(1):7-25. PubMed ID: 36692150
    [TBL] [Abstract][Full Text] [Related]  

  • 72. A combo-strategy to improve brain delivery of antiepileptic drugs: Focus on BCRP and intranasal administration.
    Gonçalves J; Silva S; Gouveia F; Bicker J; Falcão A; Alves G; Fortuna A
    Int J Pharm; 2021 Jan; 593():120161. PubMed ID: 33307160
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Compartment-specific roles of ATP-binding cassette transporters define differential topotecan distribution in brain parenchyma and cerebrospinal fluid.
    Shen J; Carcaboso AM; Hubbard KE; Tagen M; Wynn HG; Panetta JC; Waters CM; Elmeliegy MA; Stewart CF
    Cancer Res; 2009 Jul; 69(14):5885-92. PubMed ID: 19567673
    [TBL] [Abstract][Full Text] [Related]  

  • 74. A2A adenosine receptor stimulation decreases foam cell formation by enhancing ABCA1-dependent cholesterol efflux.
    Bingham TC; Fisher EA; Parathath S; Reiss AB; Chan ES; Cronstein BN
    J Leukoc Biol; 2010 Apr; 87(4):683-90. PubMed ID: 20089670
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Specific increase in MDR1 mediated drug-efflux in human brain endothelial cells following co-exposure to HIV-1 and saquinavir.
    Roy U; Bulot C; Honer zu Bentrup K; Mondal D
    PLoS One; 2013; 8(10):e75374. PubMed ID: 24098380
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Enhancing Brain Retention of a KIF11 Inhibitor Significantly Improves its Efficacy in a Mouse Model of Glioblastoma.
    Gampa G; Kenchappa RS; Mohammad AS; Parrish KE; Kim M; Crish JF; Luu A; West R; Hinojosa AQ; Sarkaria JN; Rosenfeld SS; Elmquist WF
    Sci Rep; 2020 Apr; 10(1):6524. PubMed ID: 32300151
    [TBL] [Abstract][Full Text] [Related]  

  • 77. P-glycoprotein Inhibitor Tariquidar Potentiates Efficacy of Astragaloside IV in Experimental Autoimmune Encephalomyelitis Mice.
    Zhang W; Liu M; Yang L; Huang F; Lan Y; Li H; Wu H; Zhang B; Shi H; Wu X
    Molecules; 2019 Feb; 24(3):. PubMed ID: 30717494
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Induction of drug efflux protein expression by venlafaxine but not desvenlafaxine.
    Bachmeier CJ; Beaulieu-Abdelahad D; Ganey NJ; Mullan MJ; Levin GM
    Biopharm Drug Dispos; 2011 May; 32(4):233-44. PubMed ID: 21446053
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Distribution of gefitinib to the brain is limited by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2)-mediated active efflux.
    Agarwal S; Sane R; Gallardo JL; Ohlfest JR; Elmquist WF
    J Pharmacol Exp Ther; 2010 Jul; 334(1):147-55. PubMed ID: 20421331
    [TBL] [Abstract][Full Text] [Related]  

  • 80. P-glycoprotein and breast cancer resistance protein affect disposition of tandutinib, a tyrosine kinase inhibitor.
    Yang JJ; Milton MN; Yu S; Liao M; Liu N; Wu JT; Gan L; Balani SK; Lee FW; Prakash S; Xia CQ
    Drug Metab Lett; 2010 Dec; 4(4):201-12. PubMed ID: 20670210
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.